|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 2/13/2025
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
Machine Learning Diagnostic for Automated Identification and Classification of Bone Marrow Cells
Application
Machine learning tool to aid in the diagnosis of hematologic disorders of bone marrow.
Key Benefits
Automated machine learning-based approach for performing bone marrow differential counts that accounts for all viable cells on the smear.
Data generated by a prototype shows the system is fast and demonstrates precision compared to manual...
Published: 2/13/2025
Contributor(s): Lee Cooper, David Gutman, David Jaye, Ahmed Aljudi, Ramraj Chandradevan
|
|
Machine Learning Diagnostic for Automated Identification and Classification of Bone Marrow Cells
Application
Assist in the diagnosis of hematologic disorders of bone marrow.
Key Benefits
Automated machine learning approach for performing bone marrow differential counts that accounts for all viable cells on the smear.
Preliminary data generated by a prototype shows the system is fast and demonstrates precision compared to manual counting.
Potential...
Published: 2/13/2025
Contributor(s): David Jaye, Lee Cooper, Joshua Lewis, David Gutman
|
|
Blood-based Diagnostic Test for Anxiety
Application
A blood-based biomarker test for the diagnosis of anxiety disorders.
Key Benefits
Gene panel of at least seven biomarkers that may predict anxiety in humans.
Minimally invasive blood test.
May identify different forms of anxiety leading to personalized treatment and improved clinical outcomes.
Market Summary
Anxiety disorders are...
Published: 2/13/2025
Contributor(s): Reid Alisch, Pankaj Chopra
|
|
Antisense Oligonucleotides Therapeutics Targeting Specific Tissues or Cells
Application
Antisense oligonucleotide (ASO) therapies for the treatment of rare diseases and cancer.
Key Benefits
Novel approach to ASO therapeutics that potentially improve tissue/cell targeting capabilities.
Increases the efficacy of ASOs while decrease off-target toxicity.
Potential to treat a variety of genetic diseases such as cancer, blood...
Published: 2/13/2025
Contributor(s): Jiahui Zhang, Khalid Salaita, Hanjoong Jo
|
|
Central Line-Associated Bloodstream Infection (CLABSI) Prediction Model
Application
A predictive model of central line-association bloodstream infection (CLABSI).
Key Benefits
Specifically designed to improved predictive analysis of patients who are at risk for CLABSI.
Scored higher predictive values on average than similar predictive modeling without the hypotheses driven approach (Bidirectional LSTM with...
Published: 2/13/2025
Contributor(s): Azade Tabaie, Rishikesan (Rishi) Kamaleswaran, Evan Orenstein
|
|
Micron-Sized Drug Vehicle for Unregulated Blood Clotting
Application
Fibrinogen-coated micron-sized drug vehicles for targeted treatment of unregulated blood clotting.
Key Benefits
Facilitates targeted release of drugs specifically for blood clotting disorders.
Drug delivery vehicle can be used with newly discovered or known therapeutics on the market.
Site specific biological mechanism may help increase...
Published: 2/13/2025
Contributor(s): Caroline Hansen, Yumiko Sakurai, Wilbur Lam, Andrew Lyon
|
|
Algorithm and Software Application for the Diagnosis of Adverse Reactions to Blood Transfusion
Application
Web-based and mobile application based on the National Healthcare Safety Network’s Biovigilance Component Hemovigilance Module Surveillance Protocol to aid in the identification of adverse reactions to transfusions easily and accurately.
Key Benefits
Provides a quick, easy, and accurate method to identify transfusion reactions...
Published: 2/13/2025
Contributor(s): John Roback, Geoffrey Smith
|
|
P-selectin Inhibitor for the Treatment of Sickle Cell Disease
Application
A glycopeptide inhibitor of p-selectin for the treatment of sickle cell disease.
Key Benefits
Blocks the activity of P-selectin with nM affinity.
Potential treatment for vaso-occlusive crisis associated with sickle cell disease.
Inhibits the earliest stage of leukocyte activation helping to prevent immune response.
Market Summary
Sickle...
Published: 2/13/2025
Contributor(s): Richard Cummings, Elliot Chaikof, Venkata Krishnamurthy, Mohammed Sardar
|
|
Newborn Pulse Oximetry Data Interpretation Software and Mobile App
Application
Web software and mobile app for interpreting and qualifying newborn pulse oximetry data.
Key Benefits
Reduces interpretation of pulse oximetry data.
Provides decision support type feedback.
Based upon algorithm endorsed by the American Academy of Pediatrics and the American Heart Association.
Market Summary
The use of pulse oximetry...
Published: 2/13/2025
Contributor(s): Matthew Oster
|
